NCT00667654View on ClinicalTrials.gov

Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

August 31, 2016

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

CNTX-4975

Testing a range of dosing configurations to optimize patient tolerability

Trial Locations (1)

01610

Clinical Phamacology Study Group, Worcester

Sponsors
All Listed Sponsors
lead

Centrexion Therapeutics

INDUSTRY

NCT00667654 - Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA) | Biotech Hunter | Biotech Hunter